‘Global Inflammatory Bowel Diseases Drug Market Worth $9.5bn In 2020’ Says Visiongain Report

22 August 2018
Pharma

Visiongain’s new report Global Inflammatory Bowel Diseases Drug Market Report: Aminosalicylates, Antibiotics, Corticosteroids, Immunomodulators, Biologics, Crohn’s Disease, Ulcerative Colitis indicates that the global Inflammatory Bowel Diseases drug market will see $9.5bn in spending in 2020.

The global inflammatory bowel diseases (IBD) drug market is estimated at $8.5bn in 2016 and $9.5bn in 2020. Biologic therapies are expected to be the main drivers of growth in the world IBD drug market over the forecast period. In 2016, the biologics submarket generated revenues of $5.8bn, accounting for 68% of the global IBD drug market.

The lead analyst of the report said: “The worldwide inflammatory bowel drug market will show moderate sales growth over the next four years from 2016. Patent expiries for Humira and Remicade during our forecast period will bring the market value significantly lower. New drugs entering the market are not expected to be able to offset this loss.

The increased use of biologics will be the main sales driver to 2027. Aminosalicylates, however, will remain an important option for patients, especially those in poor countries, as the cost advantage of aminosalicylates will be more pronounced in those regions.”

The 200-page report contains 89 tables and 50 figures that add visual analysis in order to explain the developing trends within the Global Inflammatory Bowel Diseases drug market. Visiongain provides revenue forecasts for the period 2017-2027 as well as qualitative analyses for the leading segments of this market: Biologics, Aminosalicylates, Antibiotics, Corticosteroids, Immunomodulators.

Our study forecasts individual revenues of 17 leading IBD drugs, including these drugs: Humira, Remicade, Asacol, Pentasa, Lialda, Tysabri.
This report also discusses research and development, including drug candidates in these classes: Interleukin (IL) inhibitors, Cell-adhesion molecule (CAM) inhibitors, TNF-alpha inhibitors, Stem cell therapies, JAK inhibitors and Toll-like receptor agonists.

The 200-page report offers market forecasts and analysis for 11 leading national markets and the rest of the world market. In addition, the report contains a dedicated leading companies’ chapter covering companies leading the field in the inflammatory bowel diseases drug market.

The Global Inflammatory Bowel Diseases (IBD) Drug Market Forecast 2017-2027: Aminosalicylates, Antibiotics, Corticosteroids, Immunomodulators, Biologics, Crohn’s Disease, Ulcerative Colitis report will be of value to anyone who wants to better understand the Global Inflammatory Bowel Diseases drug market and its various segments. It will be useful for businesses who wish to better comprehend the part of the market they are already involved in, or those wishing to enter or expand into a different regional or technical part of Global Inflammatory Bowel Diseases drug market and industry.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business conferences, newsletters, management reports and e-zines focusing on the automotive, chemical, cyber, defence, energy, pharmaceutical, materials and telecoms sectors.

Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Dermatological Drugs Market Report 2021-2031

The global market for dermatological drugs is ascending and has made significant gains in skin treatments. The players in the dermatological drugs market are striving to tap the opportunities that this market offers.

18 January 2021

Read

Visiongain Publishes Antigen Skin Test Market Report to 2031

The study covers detailed and insightful chapters on market overview, market segments, new developments, competitive landscape, strategic recommendations, key company analysis, market opportunities, pricing analysis, gap analysis, porter’s 5 forces model, company profiling, geographical analysis, and analytical overview of the market. Increasing health concerns among population and growing incidences of fungal & bacterial infection are some of the factors driving the growth of Antigen Skin Test market.

12 January 2021

Read

Visiongain Publishes Top 50 Pharmaceutical Contract Manufacturing Organisations (CMOs) Market Report 2021

Fierce competition, stringent regulations, diminishing research and development, shrinking margins, strong price pressures and patent cliffs encompass today’s drug industry. It is a well-known fact that future of the pharmaceutical/biopharmaceutical industry depends on innovation, and innovation comes from collaborations or partnerships.

11 January 2021

Read

Visiongain Publishes Anti-Infective Vaccines Market Report Report to 2031

The study covers detailed and insightful chapters on market overview, market segments, new developments, competitive landscape, strategic recommendations, key company analysis, market opportunities, pricing analysis, gap analysis, porter’s 5 forces model, company profiling, geographical analysis, and analytical overview of the market.

11 January 2021

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever